Methyldopa (versus unexposed)

Study Reference
Al Khalaf (Controls unexposed, disease free), 2022

Al Khalaf Role of Antihypertensive Treatment and Blood Pressure Control in the Occurrence of Adverse Pregnancy Outcomes: a Population-Based Study of Linked Electronic Health Records. Hypertension 2022; 79:1548-1558

Al Khalaf (Controls unexposed, sick), 2022

Al Khalaf Role of Antihypertensive Treatment and Blood Pressure Control in the Occurrence of Adverse Pregnancy Outcomes: a Population-Based Study of Linked Electronic Health Records. Hypertension 2022; 79:1548-1558

Chan, 2010

Chan WS Neurocognitive development of children following in-utero exposure to labetalol for maternal hypertension: a cohort study using a prospectively collected database. Hypertens Pregnancy 2010;29:271-83

De Jonge, 2013

de Jonge Identifying associations between maternal medication use and birth defects using a case-population approach: an exploratory study on signal detection. Drug Saf 2013; 36:1069-78

Fidler, 1983

Fidler Randomised controlled comparative study of methyldopa and oxprenolol in treatment of hypertension in pregnancy. Br Med J (Clin Res Ed) 1983; 286:1927-30

Fisher (Controls unexposed, disease free), 2017

Fisher Maternal Antihypertensive Medication Use and Congenital Heart Defects: Updated Results From the National Birth Defects Prevention Study. Hypertension 2017; 69:798-805

Fisher (Controls unexposed, sick), 2017

Fisher Maternal Antihypertensive Medication Use and Congenital Heart Defects: Updated Results From the National Birth Defects Prevention Study. Hypertension 2017; 69:798-805

Hoeltzenbein, 2017

Hoeltzenbein M Pregnancy Outcome After First Trimester Use of Methyldopa: A Prospective Cohort Study. Hypertension 2017;70:201-208

Ishikawa (Controls unexposed, disease free), 2023

Ishikawa Risk of major congenital malformations associated with first-trimester antihypertensives, including amlodipine and methyldopa: A large claims database study 2010-2019. Pregnancy Hypertens 2023; 31:73-83

Ishikawa (Controls unexposed, sick), 2023

Ishikawa Risk of major congenital malformations associated with first-trimester antihypertensives, including amlodipine and methyldopa: A large claims database study 2010-2019. Pregnancy Hypertens 2023; 31:73-83

Kayser, 2020

Kayser Neonatal effects of intrauterine metoprolol/bisoprolol exposure during the second and third trimester: a cohort study with two comparison groups. J Hypertens 2020; 38:354-361

Leather, 1968

Leather A controlled trial of hypotensive agents in hypertension in pregnancy. Lancet 1968; 2:488-90

Mabie, 1986

Mabie Chronic hypertension in pregnancy. Obstet Gynecol 1986; 67:197-205

Medveczky, 2004

Medveczky The use of drugs in mothers of offspring with neural-tube defects. Pharmacoepidemiol Drug Saf 2004; 13:443-55

Orbach, 2013

Orbach H Hypertension and antihypertensive drugs in pregnancy and perinatal outcomes. Am J Obstet Gynecol 2013;208:301.e1-6

Redman, 1976

Redman Fetal outcome in trial of antihypertensive treatment in pregnancy. Lancet 1976; 2:753-6

Sibai, 1990

Sibai A comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy. Am J Obstet Gynecol 1990; 162:960-6; discussion 966-7

Vaclavik, 2024

Vaclavik, J. MATERNAL AND FETAL OUTCOMES OF VARIOUS ANTIHYPERTENSIVE TREATMENT REGIMENS DURING PREGNANCY: INSIGHTS FROM THE CZECH NATIONAL REGISTRY 2012-2022 Int. J. Hypertens. 2024; 42:e10-.

Van Zutphen, 2014

Caton Maternal hypertension, antihypertensive medication use, and the risk of severe hypospadias. Birth Defects Res A Clin Mol Teratol 2008; 82:34-40

Van Zutphen AR Maternal hypertension, medication use, and hypospadias in the National Birth Defects Prevention Study. Obstet Gynecol 2014;123:309-17

Weitz, 1987

Weitz Treatment of hypertension in pregnancy with methyldopa: a randomized double blind study. Int J Gynaecol Obstet 1987; 25:35-40

Welt, 1981

Welt The effects of prophylactic management and therapeutics on hypertensive disease in pregnancy: preliminary studies. Obstet Gynecol 1981; 57:557-65